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ANOVA analysis of variance 
BMI body mass index 
BPAR biopsy-proven acute rejection 
CAV cardiac allograft vasculopathy 
CNI calcineurin inhibitor 
CsA cyclosporine A 
DLK1 delta-like 1 homologue 
DLL1 delta-like Notch ligand 1  
ECM extracellular matrix 
EC endothelial cell 
EVR everolimus 
HF heart failure 
hsCRP high sensitivity C-reactive protein 
HTx heart transplantation 
IVUS intravascular ultrasound 
LVEDD left ventricular end diastolic diameter 
MCP-1 monocyte chemoattractant protein 1 
MIT maximal intimal thickness 
MMF mycophenolate mofetil 
mTOR mammalian target of rapamycin 
mTORC mTOR complex 
NF nuclear factor 
NT-proBNP N-terminal pro-B-type natriuretic peptide 
PAV percent atheroma volume 
PBMC peripheral blood mononuclear cell 
POSTN periostin 
sCD25 soluble CD25 
TNF tumor necrosis factor 
SIR Sirolimus 





Cardiac allograft vasculopathy (CAV) causes heart failure after heart transplantation (HTx), 
but its pathogenesis is incompletely understood. Notch signaling, possibly modulated by 
everolimus (EVR), is essential for processes involved in CAV. We hypothesized that 
circulating Notch ligands would be dysregulated after HTx.  
We studied circulating delta-like Notch ligand 1 (DLL1) and periostin (POSTN) and CAV in 
de novo HTx recipients (n=70) randomized to standard or EVR-based, calcineurin inhibitor-
free immunosuppression and in maintenance HTx recipients(n=41).  
Compared to healthy controls, plasma DLL1 and POSTN were elevated in de novo (p<0.01; 
p<0.001) and maintenance HTx recipients (p<0.001; p<0.01). Use of EVR was associated 
with a treatment effect for DLL1. For de novo HTx recipients, change in DLL1 correlated 
with change in CAV at 1 (p=0.021) and 3 years (p=0.005). In vitro, activation of T cells 
increased DLL1 secretion, attenuated by EVR. In vitro data suggest that also endothelial cells 
and vascular smooth muscle cells (VSMC) could contribute to circulating DLL1. 
Immunostaining of myocardial specimens showed colocalization of DLL1 with T cells, 
endothelial cells and VSMC.   
Our findings suggest a role of DLL1 in CAV progression, and that the beneficial effect of 
EVR on CAV could reflect suppressive effect on DLL1.  
 
Trial registration numbers 
SCHEDULE trial: ClinicalTrials.gov NCT01266148 











Heart transplantation (HTx) remains the definitive treatment for advanced heart failure (HF), 
offering a median survival after HTx of more than 13 years 
1
. Within 5 years, however, ~30% 
of the patients develop cardiac allograft vasculopathy (CAV), an important contributor to 
adverse outcome after HTx 
2
. Clinically, CAV resembles coronary heart disease, but is 
pathologically distinct from the usual coronary atherosclerosis and may affect any graft 
vessel, with concentric, progressive thickening along the length of the vessels that ultimately 
leads to ischemia, HF and death 
3
. Multiple factors contribute to CAV development, including 
immunologic (e.g., chronic rejection process) and non-immune related responses (e.g., 
hyperlipidemia and viral infection), but the pathogenesis is incompletely understood.  
Everolimus (EVR) is an alternative or supplement to calcineurin inhibitor (CNI) 
based immunosuppressive regimen after HTx and reduces the incidence and progression of 
CAV 
4-6
. EVR, a mammalian target of rapamycin (mTOR) inhibitor, has antiproliferative 
effects on lymphocytes, vascular smooth muscle cells (VSMCs), endothelial cells (ECs) and 
fibroblasts 
7
 and attenuates the activation and inflammatory response of neutrophils in vitro 
8
. 
However, the clinical benefit of EVR in HTx correlates poorly with changes in circulating 
inflammatory and vascular markers, and the mechanism by which EVR slows CAV 
progression remains unrevealed 
5
.  
The Notch signaling pathway is essential for communication between neighboring 
cells 
9
 and processes known to contribute to CAV 
10
, like EC activation 
11
, accumulation and 
activation of immune cells 
12
, proliferation of VSMC and extracellular matrix (ECM) 
remodeling 
13,14
 and T cell activation 
15
. Activation or inhibition of Notch signaling depends 
on the configuration and interactions of canonical Notch ligands 
16
. Proteolysis induces 
secretion of extracellular domains which together with a large group of non-canonical ligands 
may modulate Notch signaling 
17
. The canonical delta-like Notch ligand 1 (DLL1) regulates 




, T cells 
20
 and EC 
21
, and in HF, circulating DLL1 is 
elevated and associated with impaired cardiac function and adverse outcome 
22,23
. To our 




non-canonical Notch ligands, delta-like 1 homologue (DLK1) is the most studied and has 
inhibitory effects on angiogenesis 
24
. Periostin (POSTN), a matricellular protein functioning 
as a non-canonical Notch ligand 
25
, is regulated in clinical myocardial injury 
26
, and is 
associated with cardiac dysfunction in end-stage HF 
23
. POSTN may modify Notch signaling 
through inhibition of DLK1 
27
 or maintenance of Notch1 receptor expression 
28
. 
Based on the involvement of Notch signaling in processes central to development and 
progression of HF and CAV, and potential modulation of Notch signaling by mTOR 
inhibition 
29
, we hypothesized that i) circulating Notch ligands would be dysregulated in HTx 
recipients, ii) EVR would affect levels of circulating Notch ligands in HTx recipients; and iii) 
circulating levels of Notch ligands would be associated with CAV progression. We tested our 
hypothesis by measuring the Notch ligands DLL1, POSTN and DLK1 in plasma from two 
cohorts of HTx recipients with EVR-based and standard immunosuppression, at different 
timepoints and accompanied by assessment of CAV.    
 
Materials and Methods 
Patient population 
Two adult HTx cohorts were included: i) de novo HTx recipients from the Scandinavian heart 
transplant everolimus de novo study with early CNI avoidance (SCHEDULE) 
4
, and ii) 




The SCHEDULE trial (ClinicalTrials.gov NCT01266148) was a 1 year, controlled 
and randomized multicenter trial and has been reported in detail 
4
. In brief; the trial was 
conducted in five Scandinavian HTx centers to evaluate if early initiation of EVR and early 
cessation of the CNI cyclosporine A (CsA) could improve renal function and hamper the 
progression of CAV. After antithymocyte globulin induction therapy, de novo HTx recipients 
were randomized to an immunosuppressive regimen consisting of either i) low-dose EVR, 
CsA, mycophenolate mofetil (MMF) and corticosteroids with CsA withdrawal and stepwise 




or ii) standard regimen with CsA, MMF, and corticosteroids (hereafter: CNI group, CNI). The 
two regimens were initiated no later than the fifth postoperative day. After the 1 year trial, 
immunosuppression was according to the investigator’s preference, and the patients were 
reassessed at 3 years post HTx 
31
. A total of 70 patients (CNI, n=34; EVR, n=36) with plasma 
collected at ≥3 timepoints: 7-11 weeks (i.e., baseline), 6 months, 1 year and 3 years post HTx, 
were included in the present follow-up substudy.  
The NOCTET trial (ClinicalTrials.gov: NCT00377962) was a 1 year, controlled and 
randomized multicenter study conducted in five Scandinavian transplant centers and reported 
in detail earlier 
30
. In brief; maintenance HTx recipients with renal impairment were 
randomized to either i) EVR + reduced CNI (hereafter: Everolimus group, EVR) or ii) 
standard CNI-based regimen for maintenance immunosuppression ≥ 1 year post HTx 
(hereafter: CNI group, CNI). The aim of the study was to evaluate whether introduction of 
EVR with a simultaneous protocol-specified reduction in CNI exposure would improve renal 
function. After the 1 year core trial, the study was extended for 1 year and patients reassessed 
at their annual visit 2 years after enrollment 
32
. A total of 41 patients (CNI, n=22; EVR, n=19) 
(mean 4.7 years, range 0.9-16.9 years post HTx) with plasma collected at ≥ 3 timepoints: 
inclusion (i.e., baseline), 6 weeks and 1 and 2 years after inclusion, were included in the 
present follow-up substudy. 
For comparison, 20 age and sex matched healthy subjects were included.  
For both studies written informed consent was obtained after institutional review 
board approval. The studies were carried out in accordance with the ICH Harmonized 
Tripartite Guidelines for Good Clinical Practice, applicable local regulations and the 
Declaration of Helsinki. 
T cell isolation and activation 
Peripheral blood mononuclear cells (PBMCs) were obtained from heparin-anticoagulated 
blood from healthy donors by Isopaque-Ficoll (Lymphoprep; Axis-Shield, Oslo, Norway) 
gradient centrifugation 
33
. Isolation of T cells from PBMCs was performed by negative 




Gladbach, Germany). Isolated T cells were resuspended in AimV medium (Gibco, 
ThermoFisherScientific, Waltham, MA), seeded into a 48 well plate (Costra, Cambridge, 
MA; 250.000 cells/well), and incubated for 40 minutes in a humidified CO2 incubator at 37ºC 
before adding EVR (Sigma-Aldrich, St. Louis, MO), sirolimus (SIR) (Rapamycin, InvivoGen, 
San Diego, CA), or CsA (Sigma-Aldrich) in different concentrations. After 90 minutes of 
incubation the cells were activated by beads coated with antibodies to CD2, CD3 and CD28 
(T cell activation/expansion kit, Miltenyi Biotec). Cell-free supernatants and cell pellets were 




Baseline demographics and characteristics were comparable between the two treatment 
groups of de novo HTx recipients (SCHEDULE population), except for measured glomerular 
filtration rate, hsCRP and total cholesterol that were higher and uric acid and NT-proBNP that 
were lower in the EVR group (Table 1). For maintenance HTx recipients (NOCTET 
population), no differences in baseline demographics and characteristics were found (Table 
1). For comparison , 20 healthy control subjects were recruited. Controls (mean age±SD: 
59.4±8.8 years) were of similar age as the NOCTET population (58.9±9.3), but non-
significantly older than the SCHEDULE population (50.5±13.7, p=0.11). Further, creatinine 
in the controls was lower (76±11 mol/l) compared to both SCHEDULE (111±41mol/l, 
p<0.001) and NOCTET (121±26mol/l, p<0.001). Women represented 35% of controls, 
which was not statistically different from SCHEDULE (24%) or NOCTET (12%) (Chi square 
p=0.11).  
Notch ligands in plasma at baseline 
Compared to healthy controls and adjusting for differences in age and creatinine, baseline 
plasma DLL1 levels were higher in de novo (SCHEDULE) (p<0.01) and in maintenance 




creatinine (r=-0.45, p<0.001), hsCRP (r=0.36, p=0.004), NT-proBNP (r=0.38, p=0.004) and 
uric acid (r=0.53, p<0.001). Similar, but more modest associations were observed for baseline 
DLL1 in NOCTET (creatinine r=-0.27, p=0.088; hsCRP r=0.28, p=0.078; uric acid r=0.33, 
p=0.042, and hemoglobin r=0.32, p=0.044). In addition, DLL1 levels at baseline in NOCTET 
were correlated with time since HTx (r=0.35, p=0.026) (Figure 1). 
Baseline POSTN levels were also higher in both groups of HTx recipients compared 
to controls, but in contrast to DLL1, the highest levels of POSTN were seen in de novo HTx 
recipients (SCHEDULE). No significant correlations between POSTN and baseline 
biochemical variables were observed in SCHEDULE. For maintenance HTx recipients 
(NOCTET), baseline POSTN levels correlated with uric acid (r=0.39, p=0.014) but not with 
time since HTx (r=0.28, p=0.085) (Figure 1).  
For DLK1, no significant differences were found (Figure 1). 
Effect of EVR on Notch ligands in plasma  
. A significant overall treatment effect was observed in the temporal course of circulating 
DLL1 for each study population (Figure 2). In de novo HTx recipients (SCHEDULE) plasma 
levels of DLL1 decreased after 6 months of EVR treatment and remained low compared to 
baseline levels, but above those of healthy controls, throughout the study. Comparing the 
change in DLL1 after adjusting for baseline DLL1 levels and change in kidney function (i.e., 
creatinine) in the same period revealed a significantly larger decrease in the EVR group at all 
timepoints. Among maintenance HTx recipients (NOCTET) a similar, but less distinct pattern 
was observed with a significant treatment effect at 1year follow-up.  
No treatment effects were observed for POSTN or DLK1 (Figure 2). POSTN levels 
declined after commencing on either of the immunosuppressive regimens in de novo HTx 
(SCHEDULE) recipients and remained low, but above those of healthy controls, for both 
treatment groups compared to baseline (Figure 2). In contrast, POSTN increased compared to 
baseline at all subsequent timepoints in both treatment groups in maintenance HTx recipients 
(NOCTET) (Figure 2). Plasma DLK1 remained stable and comparable to levels in healthy 




While DLL1 displayed similar profiles in SCHEDULE and NOCTET, POSTN 
exhibited a marked early decline in SCHEDULE, independent of study arm. The level of 
POSTN at 1 and 3 years in SCHEDULE was quite similar to NOCTET levels (i.e., median 
4.7 years post HTx) and it seems that at 6 months, “steady state” levels of POSTN are 
achieved. The reason for this pattern is unclear, but as POSTN is induced during tissue injury 
and during ECM remodeling 
34
, we suggest that the initial high POSTN levels after HTx 
reflect ongoing ECM remodeling.  
Notch ligands and acute rejections 
Similar to the original report 
31
, there was a trend association between biopsy-proven acute 
rejection (BPAR) and the use of EVR (32% vs. 13%, p=0.056), EVR and CNI, respectively). 
As depicted in Supplemental Table 1, we observed, however, no difference in change in 
DLL1 between patients with and without BPAR, although there was a trend toward lower 
DLL1 levels in patients who experienced BPAR within the first year (p=0.090). No 
differences in change- or 1-year levels of DLL1 in relation to BPAR were observed within the 
treatment arms. For the other ligands, the decline in POSTN during 1 year follow-up was 
larger in those who experienced BPAR. 
DLL1 and CAV development      
Recently, we reported attenuated CAV development in the EVR group of de novo HTx 
recipients (SCHEDULE) 
5
. Herein, we observed a treatment effect for DLL1. We therefore 
evaluated the relationship between change in DLL1 (∆DLL1) and CAV development in the 
SCHEDULE population. A positive correlation between ∆DLL1 and change in maximal 
intimal thickness (∆MIT) from baseline to 1 (r=0.31, p=0.016) and 3 years (r=0.39, p=0.006) 
was noted, primarily reflecting changes in the CNI group (Figures 3A and 3B). However, we 
found no correlation between MIT and DLL1 levels at the individual time points. ∆DLL1 
could potentially reflect improved allograft function, but correlations with changes in 
allograft function [i.e., left ventricular ejection fraction (LVEF), left ventricular end diastolic 
diameter (LVEDD), peak early diastolic mitral inflow velocity/ peak late diastolic mitral 




(Supplemental Table 2). However, ∆DLL1 correlated with change in CRP (r=0.30, p=0.018), 
mainly driven by a correlation in the CNI group (r=0.58, p=0.001), and creatinine (r=0.49, 
p<0.001) where the correlation was present in both treatment groups (Supplemental Table 2). 
For the whole study population, the association between ∆DLL1 and ∆MIT was sustained 
when treatment, ∆NT-proBNP and ∆creatinine were included in a linear regression model 
(Figure 3C). These data support that the association between changes in circulating DLL1 and 
MIT are independent of changes in allograft or kidney function. Moreover, changes in percent 
atheroma volume (∆PAV), an additional marker of CAV development also downregulated by 
EVR in the SCHEDULE population 
5
, were also significantly correlated with ∆DLL1 at 1 and 
3 years, primarily reflecting changes in the CNI group, and again, independently of allograft 
or kidney function (Figure 3C).  
Effect of EVR on Notch ligand DLL1 in myocardial tissue 
To assess whether the observed effects of EVR on DLL1 could be observed in the 
myocardium, we determined expression of mRNA for DLL1 and Notch receptors 1 and 2 in 
myocardial tissue from both study arms (EVR, n=14; CNI, n=18) in the SCHEDULE 
population. Whereas DLL1 was downregulated in the EVR group, NOTCH1/2 were similar 
between the groups (Figure 4C). Importantly, DLL1 correlated with MIT 1 year post-HTx for 
both study groups (n=28, r=0.40, p=0.003) (Figures 4D and 4E), and a similar finding was 
also found between DLL1 and PAV (r=0.36, p=0.057). DLL1 also correlated with LVEDD 
and NOTCH1 was correlated with NT-proBNP, suggesting some association with allograft 
function (Figure 4D).  
EVR suppresses DLL1 in activated T cells 
Activated T cells are involved in the pathogenesis of CAV 
35
, and Notch and mTOR signaling 
are crucial contributors in T cell-mediated immune responses. We therefore evaluated the 
effect of different concentrations of EVR (4, 12 and 40 ng/mL) on DLL1 release. Activation 
of T cells was associated with a time dependent increase in DLL1 and the T cell activation 
marker soluble (s)CD25 as compared to unstimulated cells (Figure 5A). EVR attenuated 




in further decreasing DLL1 and sCD25 release at the highest doses (Figure 5 B/C). Using 
even higher doses (100 and 500 ng/mL) had limited effects (Supplemental Figure 1A). A 
similar dose-response pattern has previously been reported of rapamycin on activated T cell 
production of Th1/Th2 cytokines 
36
, and importantly, the lower doses are relevant to targeted 
concentrations of EVR in the HTx patients (6-10 ng/mL in the SCHEDULE and 3-8 ng/mL in 
the NOCTET study). Stimulation of activated T cells with the mTOR inhibitor sirolimus, but 
not the CNI CsA, dampened the DLL1 and sCD25 release in a pattern similar to EVR, 
whereas CNI reduced sCD25 release dose dependently at 72 hours (Supplemental Figure 2). 
These results suggest that the observed effects on circulating DLL1 in the EVR group may be 
mediated by T cells, attributable to EVR exposure rather than freedom from CNI. Moreover, 
in activated T cells, EVR attenuated mRNA expression of the mTOR-responsive gene UTP15 
(Supplemental Figure 1B) in a similar pattern to DLL1 and sCD25, supporting a link between 
mTOR complex (mTORC) signaling and DLL1 release. Contrary to the effects on DLL1, the 
effect of EVR on mRNA levels of Notch receptors 1 and 2 was more complex with a 
reduction of NOTCH1 in un-activated T cells, and a dose dependent increased NOTCH1 in 
activated T cells at 72 hours (Supplemental Figure 3).  
ECs and VSMCs may be sources of circulating DLL1  
DLL may be released from other cells than T cells, potentially contributing to circulating 
DLL1 in HTx recipients. To elucidate this, we examined the release DLL1 from VSMCs, 
human aortic and umbilical vein ECs and cardiac fibroblasts. These experiments revealed 
(Supplemental Figures 4/5/6): i) VSMC and ECs, but not cardiac fibroblasts, secrete DLL1 in 
the conditioned medium and could be potential sources for circulating DLL1 in addition to T 
cells, ii) Activation of VSMC with the prototypical upstream inflammatory cytokine 
interleukin 1β enhanced DLL1 secretion, while the release of DLL1 upon tumor necrosis 
factor (TNF)-mediated endothelial cell activation, another prototypical upstream 
inflammatory cytokine, was more modest, iii) EVR attenuated DLL1 release. 




Our findings so far show that DLL1 mRNA are expressed in myocardial tissue following 
HTx. Our in vitro studies suggest that T cells, ECs and VSMCs could be important cellular 
sources of DLL1. To further elucidate these findings, we performed immunohistochemistry 
analysis of myocardial specimens from two HTx recipients with high MIT (0.90 and 
0.81mm), indicative of presence of CAV. The biopsies were obtained at the first annual post-
HTx visit for participants in the SCHEDULE trial (Figure 6). DLL1 protein was expressed in 
myocardial tissue and exhibited a distribution pattern corresponding to presence of T cells, 
ECs and VSMCs. Although we were unable to firmly establish the proximity to CAV in our 
specimens, the strong staining of the EC marker CD31, in the upper right corner of Figure 6C 
could reflect endothelial activation, a common feature of CAV 
37
.     
 
Discussion 
We studied circulating Notch ligands DLL1, POSTN and DLK1 and CAV in HTx recipients 
receiving standard or EVR-based, CNI-free immunosuppression and in maintenance HTx 
recipients. Our main findings were: i) In HTx recipients, plasma DLL1 and POSTN were 
elevated compared to healthy controls, ii) use of EVR-based, CNI-free immunosuppression 
was associated with decreased plasma DLL1 levels, iii) during long-term follow-up, changes 
in plasma DLL1 in de novo HTx recipients correlated with changes in markers of CAV (MIT 
and PAV), iv) in myocardial tissue from de novo HTx recipients, the DLL1 protein was 
expressed in a distribution pattern similar to T cells, ECs and VSMCs, and DLL1 mRNA 
levels were attenuated in the EVR group and correlated with CAV (MIT and PAV), v) in 
vitro, activation of T cells increased DLL1 secretion, and EVR and sirolimus, but not CsA, 
attenuated this release, vi) ECs and VSMCs released DLL1, with attenuating effects of EVR 
in EC. These findings suggest a link between CAV development and DLL1 involving a 
complex interaction between T cells, VSMCs and ECs, also within the heart allograft.  
As in chronic HF, circulating DLL1 levels at baseline in de novo HTx recipients 
correlated with kidney function 
38
. More importantly, enhanced DLL1 levels compared to 




systemic inflammation as reflected by hsCRP and in particular uric acid, which is markedly 
elevated early after HTx, potentially reflecting increased metabolic and oxidative stress 
39
. 
The persistently elevated DLL1 levels, suggesting enhanced Notch pathway activity, could 
mean that DLL1 is a marker of these processes, but also indicate that Notch signaling and 
DLL1 contribute to inflammation, endothelial activation and metabolic and oxidative stress in 
HTx recipients. Furthermore, DLL1 is central in T cell-mediated responses 
40
, and 




. While T 
cell activation may be important for maintaining adaptive immune responses, dysregulated T 
cell activation may cause maladaptive immune response characterized by extensive 
production of inflammatory cytokines. The release of DLL1 from activated T cells in our in 
vitro study may propose DLL1 to be a part in a pathogenic loop leading to enhanced T cell 
activation in HTx recipients and potentially maladaptive T cell responses.  
A major finding was that EVR downregulated DLL1 in vivo. Our in vitro findings 
show a similar effect of sirolimus, but not the CNI CsA, suggestive of mTORC involvement, 
but the underlying mechanisms are not clear. mTORC regulates several pathways relevant for 
T cell activation such as Nuclear Factor (NF)-κB, and is activated by the Akt pathway, which 
links T cell activation to mTORC 
42
. Since the pattern of DLL1 release mimics that of sCD25, 
it is tempting to hypothesize that DLL1 could be directly regulated through mTORC. TNF, 
the prototypical activator of NF-κB, has been shown to increase DLL1 expression in 
fibroblast like cells 
43
. Furthermore, another mTORC inhibitor, Torin-1, decreased the 
expression of DLL1 in vivo in colorectal cancer xenografts 
44
. Moreover, the release of DSL 
ligands including DLL1 is achieved by shedding induced by ADAM9/10/12 
45-47
, and 
interestingly rapamycin (i.e., sirolimus) has been shown to inhibit ADAM10 
48
 and ADAM12 
49,50
. Thus, both direct mTOR mediated effects as well as protease activity that is also 
influenced by the mTOR pathway could contribute to DLL1 release.  
Neointimal proliferation and infiltration by macrophages are principal to CAV 
development and likely driven by several processes including upstream cytokine production 




the thickened intima 
51
, and the beneficial effect of EVR on CAV development as reported in 
the SCHEDULE population 
5
 may mirror attenuation of T cell activation. However, the 
molecular mechanism for the beneficial effect of EVR on CAV is not clear. Our previous 
attempts to identify associations between the effect of EVR on CAV and effects on a wide 
range of inflammatory markers, including CRP, have failed. Our present findings that EVR 
downregulates DLL1 both in plasma and the myocardium, and that DLL1 correlates with 
MIT and PAV, reflective of CAV development, may suggest that the beneficial effects of 
EVR on CAV could involve downregulation of DLL1 and Notch signaling. Interestingly, in 
experimental HTx, blockade of transcriptional activation downstream of all Notch receptors 
in T cells eliminated the effects of canonical Notch signaling and improved graft survival 
52
. 
EC injury from immunologic and non-immunologic factors is central to CAV development 
3
, 
and Notch signaling is involved in EC dysfunction 
11
. Herein we show that ECs release 
DLL1, attenuated by EVR. Thus, it is tempting to hypothesize that the beneficial effect of 
EVR in CAV could involve attenuated Notch signaling with inhibitory effects on DLL1 
release from T cells and ECs. Although we lack data on the effects of EVR on DLL1 protein 
levels in the myocardium, the immunostaining showing colocalization of DLL1 to markers of 
T cells and ECs within the myocardium in CAV patients, may suggest that such mechanisms 
also could be operating in vivo within the myocardium in HTx recipients with CAV.  
In vivo, EVR decreased DLL1 in plasma and myocardium from HTx recipients. In 
contrast to circulating DLL1 where the temporal change in DLL1 and not the level at a 
specific time point correlated with change in MIT and PAV, myocardial DLL1 correlated 
with MIT and PAV in biopsies taken 1 year after post-HTx. This “disassociation” between 
plasma and myocardial DLL1 may suggest that circulating DLL1 at a single timepoint may 
reflect the contribution of multiple cell types in the body, some of which may not be involved 
in CAV progression, while the change in circulating DLL1 over time to a larger extent may 
mirror concerted long-term changes during CAV progression. On the other hand, myocardial 
mRNA levels of DLL1 presumably mainly reflects DLL1 in ECs, VSMCs and immune cells 




Limitations to the present study include the relatively small sample sizes and the 
homogenous Scandinavian population. Thus, the SCHEDULE and NOCTET study 
populations may differ from the global HTx recipient population, which may constrain the 
extrapolation of our results. Moreover, lack of blood samples obtained before HTx limits the 
ability to interpret the pattern of DLL1 levels after HTx. Further, associations do not 
necessarily imply any causal relationship, and we lack data on Notch signaling within the 
CAV lesions and relevant cells (i.e., T cells and ECs), and analysis of their DLL1 mRNA and 
protein expression could illuminate our findings. Mechanistic data on effects of mTOR 
inhibition on ligand-receptor interactions would have strengthen our findings. For our 
experiment on the effect of EVR on NOTCH1/2 mRNA expression in activated T cells it 
might have been informative to in parallel quantify the corresponding receptor proteins and 
DLL1, as others have reported an upregulation of NOTCH1 proteins after anti-CD3/28 
stimulation of T cells 
53
. Whereas plasma DLL1 performs technically well, and displays good 
coefficients of variation and no diurnal or postprandial variation 
54
, less is known for POSTN. 
To illuminate the robustness of our findings, the stability of DLL1 in samples thawed more 
than once, could have been measured. Unfortunately, we have no data on freeze/ thaw 
stability for DLL1 for the present study. Finally, other Notch ligands, such as DLL3/4, Jagged 
1/2 could also be involved in CAV development. Future studies should address the limiting 
issues of the present trial. 
We conclude that in HTx recipients, DLL1 is increased and downregulated by EVR-
based immunosuppression, and change in DLL1 is correlated with CAV progression. Our 
findings may suggest a role for Notch signaling and DLL1 in CAV progression.   
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Figure 1. Circulating Notch ligands at baseline in the SCHEDULE (n = 70, 7-11 weeks post 
heart transplant) and NOCTET (n = 41, mean time since heart transplant: 4.7 years) trials and 
healthy controls (CTR, n = 20). Data are given as median and interquartile range. **p<0.01, 
***p<0.001P-values adjusted for age and creatinine using ANCOVA with Bonferroni 
adjusted post-hoc tests. 
 
Figure 2. Circulating Notch ligands during long-term follow-up in the SCHEDULE and 
NOCTET trials. Data are given as estimated marginal means and 95% CI. The p-value 
indicates the group effect of treatment from repeated measures ANOVA using baseline levels 
as a covariate. The grey shaded areas represent the geometric mean (grey line) and 95% CI 
for healthy controls, n = 20. *p<0.05, **p<0.01, ***p<0.001 vs. baseline (BL). †p<0.05 
comparing change at the indicated timepoint between standard treatment (CNI) vs. everolimus 
adjusting for baseline levels and change in creatinine in the same period. 
 
Figure 3. Association between cardiac allograft vasculopathy progression and change in 
DLL1. The plots show the correlation between change in maximal intimal thickness (MIT) 
and percent atheroma volume (PAV) and DLL1 at A) 1 and B) 3 years. The numbers show 
the Spearman correlation coefficient and p-value for the total population (black) and in the 
CNI (blue) and everolimus (red) treatment arms. C) linear regression analysis of change in 
MIT and PAV at 1 and 3 years with treatment and change in DLL1, creatinine and N-terminal 
pro-B-type natriuretic peptide (NT-proBNP) for the same period as predictors. Beta: 
standardized regression coefficient; t: t statistic, p: probability. 
 
Figure 4. Effect of everolimus on the expression of Notch in myocardial tissue. A) integrity 
of mRNA from endomyocardial biopsies (n=27) obtained at the 1 year control from the 
SCHEDULE population. Left lane is the ladder while the two right lanes are mRNA from 




(DLL1, NOTCH1/2, GAPDH cardiac tissue; NOTCH3/4). C) mRNA expression of NOTCH, 
NOTCH2 and DLL1 in endomyocardial biopsies (CNI group n=15; Everolimus group n=12) 
obtained 1 year after heart transplantation. *p<0.05(Mann-Whitney U test). D) correlation 
between mRNA of DLL1, NOTCH1, NOTCH2 and circulating (c) biomarkers and indices of 
allograft function. The numbers represent Spearman correlation coefficients (blue p<0.05, red 
p<0.01). E) correlation between maximal intimal thickness (MIT) and DLL1 mRNA 1 year 
after heart transplantation (showed as ln transformed values). Experiments were run in 
duplicates.  
 
Figure 5. Modifying effect of everolimus (EVR) on DLL1 secretion from activated T cells. 
A. DLL1 and sCD25 levels in conditioned media from T cells activated with beads coated 
with antibodies to CD2, CD3 and CD28 for 24, 48 and 72 hours. B. Effect of 4, 12 and 40 ng/ 
mL EVR on DLL1 and sCD25 secretion from activated T cells (anti-CD2/3/28) after 24 hours 
and C. 72 hours. *p<0.05, **p<0.01, ***p<0.001 vs. activated T cells (anti-CD2/3/28). 
†p<0.05, ††p<0.01, †††p<0.001 vs. cells activated T cells treated with 4 ng/mL EVR 
(Student T-test). T cells from three healthy donors, experiments were run in triplicates. US: 
unstimulated T cells. White bars: unstimulated T cells; grey bars: activated T cells; black 
bars: activated T cells treated with EVR. 
 
Figure 6. Expression of DLL1 in endomyocardial biopsies obtained at the first annual post-
HTx visit. Localization of A) CD3
+
 cells as a marker of T cells, and B) expression in 
consecutive tissue slide of DLL1 as identified by immunostaining with 3,3′-
Diaminobenzidine (DAB); C) CD31
+
 cells as a marker of endothelial cells, and D) expression 
in consecutive tissue slide of DLL1; E) Alfa smooth muscle actin (αSMA)
+
 cells as a marker 
of vascular smooth muscle cells, and F) expression in consecutive tissue slide of DLL1. 
Immunofluorescence visualization was performed by the Tyramide signal amplification 




vascular smooth muscle cells (panel E) and corresponding DLL1 expression (panels B,D and 
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